Kazia Therapeutics Recognized as “Drug Discovery Company of the Year” in 2026 BioTech Breakthrough Awards
Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
INOVIQ SIGNS AGREEMENT WITH SONIC HEALTHCARE USA TO VALIDATE OVARIAN CANCER TEST AND EXPLORE POTENTIAL FUTURE US COMMERCIALISATION
Crossbench calls for scrutiny of Research and Development (R&D) tax incentive changes which put our medical research sector at risk.
It’s no secret drug firms donate to political parties. But it’s still a secret exactly how much, and why
Clarity Pharmaceuticals: SECuRE update: recruitment target of the Cohort Expansion Main Group achieved
Syntara: Additional data from SNT-4728 Phase 2 study shows significant improvement in clinician assessed motor signs
Imugene Reports one Complete Response and one Partial Response in BTKi Combination Cohort of azer-cel Phase 1b Trial
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
AdAlta: EW-001 Joint Development Committee approves FDA briefing pack and manufacturing technology transfer plan
NeuroScientific (ASX: NSB) appoints Southern Star Research to advance Phase 2 Crohn’s disease trial – Jane Morgan Management
LTR Pharma: Final Phase II report confirms SPONTAN®six-fold faster absorption and completes FDA pharmacokinetic database